Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue: 2015-2025

Historic Current Deferred Revenue for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $24.8 million.

  • Intellia Therapeutics' Current Deferred Revenue fell 44.63% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year decrease of 44.63%. This contributed to the annual value of $38.9 million for FY2024, which is 36.19% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Current Deferred Revenue is $24.8 million, which was down 16.53% from $29.7 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Current Deferred Revenue high stood at $127.2 million for Q4 2021, and its period low was $24.8 million during Q3 2025.
  • For the 3-year period, Intellia Therapeutics' Current Deferred Revenue averaged around $40.8 million, with its median value being $38.9 million (2024).
  • As far as peak fluctuations go, Intellia Therapeutics' Current Deferred Revenue soared by 166.47% in 2021, and later crashed by 67.62% in 2023.
  • Intellia Therapeutics' Current Deferred Revenue (Quarterly) stood at $127.2 million in 2021, then slumped by 49.88% to $63.8 million in 2022, then dropped by 4.36% to $61.0 million in 2023, then tumbled by 36.19% to $38.9 million in 2024, then slumped by 44.63% to $24.8 million in 2025.
  • Its Current Deferred Revenue stands at $24.8 million for Q3 2025, versus $29.7 million for Q2 2025 and $33.8 million for Q1 2025.